Tariffs and Trade Pressures in Orthopedics: Rewiring Strategies for Resilience

Tariff pressures are reshaping the global orthopedic landscape, prompting manufacturers to adjust their operational approaches and implement strategies to reduce risks. Some companies use inventory buffering to manage short-term supply risks, while several medtech firms have announced plans to relocate production facilities or establish new operations in tariff-neutral regions. These moves reflect a broader industry trend toward enhancing operational flexibility and minimizing exposure to tariff-related cost pressures and supply chain disruptions.

• Johnson & Johnson MedTech initially anticipated a higher full-year 2025 tariff burden of $400 million but revised that estimate to $200 million in Q2 2025 because most costs were absorbed within the cost of goods sold and profit margins. Although its trauma, knee, and hip businesses remain more exposed due to reliance on imports from Switzerland and, to a lesser extent, mainland China, its sports medicine segment faces lower risk owing to its limited import dependency.
• Zimmer Biomet lowered its expected tariff impact from $60-$80 million to $40 million in Q2 2025, reflecting proactive measures such as inventory buffering and sourcing adjustments. While most of its manufacturing is U.S.-based, exposure persists in orthopedic implants produced in mainland China, leaving the company partially vulnerable to trade policy shifts.
• Stryker was less exposed to tariff impact owing to its diversified global manufacturing footprint. Without significant changes to production locations, the company continued to rely on a dual-sourcing strategy to mitigate potential disruptions.
• Smith & Nephew has minimized tariff exposure as large volumes of their products are manufactured and sourced from Malaysia, Costa Rica, and the U.S. Although some components are still sourced from mainland China, they represent only a small fraction of overall production, limiting financial risk.

Material-Level Tariff Impact on Orthopedic Supply Chains

Beyond finished products, tariffs also apply to the raw materials used in U.S. manufacturing, which could significantly impact the industry, especially for high-performance materials with limited alternative sources. Depending on the material and exporting country, tariff rates range from 10% to 50%, with country-specific rates frequently changing with ongoing negotiations and policy developments. This has created ongoing variability in supply chain costs that manufacturers must actively manage as trade dynamics evolve.

From product launches to M&A and manufacturing trends, the ODT Now delivers the orthopedic device news you need weekly. Subscribe here!

Materials Frequently Used in Orthopedic Device Manufacturing

Mitigation Strategies to Navigate Trade Pressures

These cost pressures have prompted leading companies to implement mitigation strategies. By diversifying supply chains, buffering inventories and realigning portfolios, orthopedic leaders are mitigating tariff shocks and positioning themselves for long-term stability in an increasingly complex global trade environment.

• Dual sourcing: Companies are diversifying their material sourcing to reduce dependency on single-source suppliers and tariff-heavy regions, such as Mainland China. Zimmer Biomet, for example, is pairing its mainland China-based supply channels with alternative sources in lower-tariff markets.
• Nearshoring/reshoring: Manufacturers are relocating their production facilities, bringing manufacturing closer to key markets to reduce logistics overhead—actions that have potentially helped mitigate tariff exposure. For example, Smith & Nephew shifted production from mainland China and Europe to facilities in Malaysia, Costa Rica, and the U.S.
• Inventory buffering and portfolio optimization: Zimmer Biomet proactively built  inventory in mainland China before tariffs were enacted, creating a short-term buffer to delay the immediate financial impact on products shipped into mainland China while implementing longer-term sourcing adjustments. Zimmer Biomet has also noted it may prioritize products sourced from countries with lower tariff exposure. However, this is a short-term mitigation strategy and may not be sustainable if tariffs persist or escalate.

Strategic Shifts & Innovations Supporting Resilience in a Changing Trade Environment

To navigate the changing trade environment and evolving market conditions, orthopedic device companies are re-evaluating how they manage costs, allocate resources, and optimize portfolios. This rethinking of global strategies has led to a series of company announcements around acquisitions and spin-offs.

In October 2025, Johnson & Johnson MedTech indicated its refocus on higher-margin, faster-growing segments such as cardiovascular, surgical robotics, and vision, announcing its plan to spin off its DePuy Synthes Orthopaedics unit over the next 18 to 24 months. Although the company has not cited tariffs or trade pressures as drivers of this separation, the change may give DePuy Synthes greater flexibility to manage supply chain risks, optimize its orthopedics portfolio, and consider manufacturing strategies to navigate external pressures like tariffs.

Similarly, Stryker divested its U.S. spine business, which the company described as part of efforts to increase its strategic focus and investment in areas with greater long-term growth potential. While this decision was not stated to be influenced by tariffs, the divestiture may allow Stryker to reallocate resources to priority areas of its business, such as surgical robotics, where the company continues to expand capabilities through platforms like its Mako system.

Companies are also strengthening their market positions through targeted innovations. Major players are advancing their robotics platforms, including Zimmer Biomet’s ROSA, Stryker’s Mako, and Johnson & Johnson MedTech’s VELYS. Connected implants and artificial intelligence (AI)-enabled technologies are also set to improve clinical oversight and patient outcomes. These technological developments, while not driven by trade dynamics, have the potential to offset cost pressures by differentiating product portfolios.

In September 2025, the U.S. Department of Commerce launched Section 232 national security investigations into imports of robotics and industrial machinery, as well as medical equipment and devices. While the final outcomes of the investigations have yet to be determined, Section 232 allows the U.S. administration to impose increased tariffs on imports of both finished medical devices and production equipment deemed to threaten national security. Innovation-based strategies to mitigate risks could be impacted if robotics and machinery imports are subject to new tariffs going forward.

Overall, while the global trade situation continues to fuel uncertainty, the recent actions of major competitors reflect orthopedic and medtech companies’ willingness to reassess their portfolios, rethink resource allocation, and refine their operational strategies. Recent divestitures, a renewed focus on higher-growth segments, and product and technological innovation signal that companies are positioning themselves to better navigate cost pressures and market challenges going forward.